Leflunomide therapy for adult patients with steroid-dependent minimal change disease or primary focal segmental glomerulosclerosis.

Author: Chenyang ZHAO ^{1
,

2
,

3} ; Zhao CUI ^{1
,

2
,

3} ; Yimiao ZHANG ^{1
,

2
,

3} ; Fang WANG ^{1
,

2
,

3} ; Xin WANG ^{1
,

2
,

3} ; Xuyang CHENG ^{1
,

2
,

3} ; Liqiang MENG ^{1
,

2
,

3} ; Gang LIU ^{1
,

2
,

3} ; Minghui ZHAO ^{1
,

2
,

3}
Author Information

1. Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University
2. Key Laboratory of Renal Disease, Ministry of Health of China
3. Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education of China, Beijing 100034, China.
Publication Type:Journal Article
MeSH: Adult; Cyclosporine; Glomerulosclerosis, Focal Segmental/drug therapy*; Humans; Leflunomide/therapeutic use*; Nephrosis, Lipoid/drug therapy*; Nephrotic Syndrome; Steroids
From: Chinese Medical Journal 2022;135(7):866-868
CountryChina
Language:English